Latest News & Features
Americas
Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review filing. 13 August 2015
Big Pharma
The UK Intellectual Property Office has revealed the location for the country’s central and local divisions of the forthcoming Unified Patent Court. 12 August 2015
Americas
A US court has ruled that biotechnology company Regeneron engaged in “inequitable conduct” after finding that it withheld information from a patent application for a genetically modified mouse. 11 August 2015
Americas
Medical device makers Ethicon Endo-Surgery, a subsidiary of Johnson & Johnson, and Covidien will head back to a US court after the US Court of Appeals for the Federal Circuit revived their patent dispute concerning ultrasonic surgical devices. 10 August 2015
Americas
Law firm Gibson Dunn has hired Jane Love and Robert Trenchard as partners in its New York office. 10 August 2015
Americas
The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio. 6 August 2015
Americas
Drugs companies Sandoz and Lupin have failed to reverse a US court’s ruling that they infringed patents owned by Allergan. 5 August 2015
Africa
Worldwide applications for pharmaceutical patents “peaked sharply” in 2014, reaching around 28,000, a report has shown. 4 August 2015
Americas
A Brazilian court has confirmed that a eucalyptus breed produced by biotechnology company Eldorado Brasil Celulose is genetically identical to pulp producer Fibria Celulose’s own cultivar product VTO2. 4 August 2015
Americas
Pharmaceutical company Celgene has requested that the US Patent and Trademark Office sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”. 31 July 2015